The ATDC is proud to be a Partner for Mind Medicine Australia’s International Summit on Psychedelic Therapies for Mental Illness, taking place from 18-19 November 2020 at the Sofitel Melbourne On Collins. Come join us to explore the way forward for Australia.
Mind Medicine Australia will hold a two-day International Summit on Psychedelic Therapies for Mental Illness in November 2020 in Melbourne, bringing together clinicians, scientists, academics, mental and public health professionals, philanthropists, Government, law and policy makers, business, industry, investors, consumers and other interested stakeholders.
The event will also feature a two-day pre-Summit workshop program for therapists, health professionals and members of the public who are eager to gain a detailed understanding of medicine-assisted psychotherapy for the treatment of mental illness. This will be facilitated by the leading international teachers in this field.
The Summit will feature a rich program with a mixture of international and national keynotes, master classes, hot spots, panel conversations and a gala dinner Q & A.
Leading international speakers confirmed for the 2-day summit including Australia Ambassadors include: Head of Neuropsychopharmacology at Imperial College London Prof David Nutt (UK), Executive Director of MAPS Dr Rick Doblin (USA), psychiatrist, researcher and writer Dr Ben Sessa (UK), Head of the Centre for Psychedelic Research at Imperial College London Dr Robin Carhart-Harris (UK), James B. Duke Professor of Psychology and Behavioural Economics at Duke University, Prof Dan Ariely (USA/Israel), Anthropologist, ethnobotanist and Explorer in Residence at the National Geographic Society Dr Wade Davis (Canada), Director Center for Psychedelic Therapies and Research at CIIS Professor Janis Phelps (USA), Chairman and CEO of Eleusis Shlomi Raz (USA), leading Psychotherapist and Founder of the UK TRIPP Network Maria Papaspyrou (UK), Clinical Psychologist who was part of the team working on psilocybin trials at Imperial College, Renee Harvey (UK), Associate Director of the Center for Psychedelic and Consciousness Research at Johns Hopkins University School of Medicine, Prof Matthew Johnson (USA), Founder & Executive Director Neuroscape Adam Gazzaley M.D, PHD (USA), Clinical Psychologist, Research Scientist and Author Dr Adele Lafrance (USA), Psychedelic Psychiatrist & Researcher Dr Reid Robison (USA), Health Psychologist and Director of the University of Auckland’s Health Psychology Practitioner Programme Dr Lisa Reynolds (NZ) and Deputy Secretary, Health Products Regulation Group – TGA John Skerritt and more to be announced.
Key themes will include:
- Ethical, legal and implementation frameworks for psychedelic treatments
- The current state of mental health in Australia and existing treatments
- Clinical outcomes of psychedelic treatment for mental illness
- Therapeutic mechanisms of psychedelic treatments
- Enhancing effectiveness and minimising risks for psychedelic treatment
- The way forwards for Australia: Challenges and preparation towards creating a new paradigm
Psilocybin and MDMA assisted therapies have been granted Breakthrough Therapy status by the FDA in the USA due to current promising research in the treatment of depression and PTSD. We look forward to collaborating with you to explore treatment options to help address the mental health crisis we currently face, and offer treatments to those who need it most.
Together we can change the paradigm for mental health. Please join us – we hope to see you there!
For more details and to register for tickets, please visit: https://summit.mindmedicineaustralia.org/
As a partner for this event, we are delighted to extend an invitation to you and your colleagues and networks to gather in Melbourne in November 2020. Please contact us for a discount code to redeem a 10% discount on ticket bookings.
